Amicus Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Amicus Therapeutics's estimated annual revenue is currently $91.2M per year.
- Amicus Therapeutics received $300.0M in venture funding in February 2018.
- Amicus Therapeutics's estimated revenue per employee is $164,405
- Amicus Therapeutics's total funding is $294.6M.
- Amicus Therapeutics has 555 Employees.
- Amicus Therapeutics grew their employee count by -12% last year.
- Amicus Therapeutics currently has 26 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
What Is Amicus Therapeutics?
Amicus Therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. We have a unique set of platform technologies and medicines in development for patients living with the Lysosomal Storage Disorders Fabry disease and Pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our Amicus footprint spans 27 countries including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Canada, Germany, Italy, The Netherlands, Spain, France, and Japan. More information about Amicus and our career opportunities can be found at www.amicusrx.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Jeffrey Castelli||Chief Portfolio Officer|
|Bradley Campbell||President & Chief Operating Officer||Email Available|
|Enrique Dilone||SVP, Technical Operations||Email Available|
|Hung Do||Sr. Director Of Discovery Biology|
|Jayne Gershkowitz||Chief Patient Advocate||Email Available|
|Joseph Berry||Sr. Director External Manufacturing||Email Available|
|Charlene Atkinson||Director Clinical Quality Assurance|
|Dawn Mason||Sr. Manager - Cmo Direct Materials Procurement||Email Available|
|Yelena Altman||It Project Manager / Business Analyst||Email Available|
|Tyler Johnson||Principal Investigator, In Vivo Pharmacology|
Amicus Therapeutics News
CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) today announced upcoming presentations at the ...
WHITMAN BURKE W, Director, added 4,945 shares of Amicus Therapeutics, Inc. (FOLD) to its portfolio at the rate of $10.07 per share valuing ...
Amicus Therapeutics, Inc., (FOLD) shares ended September 05, 2019 trading at $9.53 which saw uptrend of -0.52% since the beginning of ...
Amicus Therapeutics Funding
|2006-05-19||$86.2M||Undisclosed||Morgan Stanley, Goldman Sachs and Co||Article|
|2006-09-15||$60.0M||D||New Enterprise Associates||Article|
|2007-06-04||$60.0M||Undisclosed||Morgan Stanley and Co Incorpor, Merrill Lynch and Co||Article|
|2010-02-26||$18.5M||Undisclosed||Leerink Swann LLC||Article|
|2012-03-05||$54.0M||Undisclosed||Leerink Swann LLC , Cowen and Company LLC||Article|
|2014-01-02||$25.0M||Undisclosed||MidCap Financial, LLC||Article|
|2014-11-25||$103.5M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-06-15||$258.8M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-07-14||$258.8M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2018-02-19||$300.0M||Undisclosed||BofA Merrill Lynch||Article|
Amicus Therapeutics Executive Hires
|2005-01-25||John F. Crowley||Chairman / CEO||Article|
|2006-01-09||David J. Lockhart||Chf Scientific Off||Article|
|2006-04-03||Donald J. Hayden||Chairman||Article|
|2006-10-03||James E. Dentzer||CFO||Article|
|2007-03-06||John F. Crowley||President/CEO||Article|
|2011-04-19||John F. Crowley||Chairman||Article|
|2012-01-24||Bradley L. Campbell||Chief Business Officer||Article|
|2012-04-17||William D. Baird||CFO||Article|
|2015-04-28||David Allsop||SVP International||Article|
|2016-07-13||Andrew Mulberg||VP Regulatory Strategy||Article|
|2017-10-09||Michael Diem||SVP Business Corporate Development||Article|
Amicus Therapeutics New Location/Offices
|2008-09-16||San Diego, CA||Article|
Amicus Therapeutics Acquisitions
|2013-11-21||Callidus Biopharma, Inc.||Cash Deal - Not Complete||Article|
Amicus Therapeutics Hiring Plans
|Date||Number of Employees||Location||Reference|
Amicus Therapeutics Staff Cuts
|Date||Number of Employees||Location||Reference|
|2013-11-22||91 Employees or 14% Workforce||Article|